Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 618-561-0 | CAS number: 9046-10-0
Carcinogenicity
Administrative data
Description of key information
No carcinogenicity data were available specifically on the test substance. According to Annex X of REACH, a carcinogenicity study may be required if the substance has a widespread dispersive use or if there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or if there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. Based on the available data, the test substance is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 90-day dermal toxicity study. Based on the weight of evidence, there are sufficient data to conclude that the test substance is not a carcinogen.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Additional information
No carcinogenicity data were available specifically on the test substance. According to Annex X of REACH, a carcinogenicity study may be required if the substance has a widespread dispersive use or if there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or if there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. Based on the available data, the test substance is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 90-day dermal toxicity study. Based on the weight of evidence, there are sufficient data to conclude that the test substance is not a carcinogen.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
